UBS Group’s NewAmsterdam Pharma NAMS Stock Holding History

UBS Group’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.4M	Sell	794,976 -104,466	-12%	-$3.4M	﹤0.01%	2332
2025 Q4	$31.6M	Buy	899,442 +130,922	+17%	+$4.76M	0.01%	2123
2025 Q3	$21.9M	Buy	768,520 +140,801	+22%	+$3.38M	﹤0.01%	2467
2025 Q2	$11.4M	Buy	627,719 +229,576	+58%	+$4.19M	﹤0.01%	2953
2025 Q1	$8.15M	Buy	398,143 +317,933	+396%	+$7.07M	﹤0.01%	3265
2024 Q4	$2.06M	Sell	80,210 -50,030	-38%	-$1.06M	﹤0.01%	4687
2024 Q3	$2.16M	Buy	130,240 +124,171	+2,046%	+$2.15M	﹤0.01%	3911
2024 Q2	$117K	Sell	6,069 -42,210	-87%	-$847K	﹤0.01%	6075
2024 Q1	$1.14M	Buy	48,279 +47,479	+5,935%	+$964K	﹤0.01%	4490
2023 Q4	$8.94K	Buy	+800	New	+$7.33K	﹤0.01%	7519
2023 Q3	–	Sell	-183	Closed	-$2.18K	–	9798
2023 Q2	$2.18K	Buy	+183	New	+$2.43K	﹤0.01%	7799

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

UBS Group's NAMS Position: Q1 2026 in Review

UBS Group reduced its NewAmsterdam Pharma (NAMS) stake by 12% in Q1 2026, selling an estimated $3.4M and leaving 794,976 shares worth $25.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

UBS Group first reported a position in NAMS in Q2 2023 and has held it in 11 quarters since. The position peaked at $31.6M in Q4 2025. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

UBS Group held 794,976 shares of NewAmsterdam Pharma worth $25.4M as of Q1 2026.
UBS Group sold 104,466 NewAmsterdam Pharma shares in Q1 2026, an estimated $3.4M.
NewAmsterdam Pharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2332 holding.
UBS Group first reported a position in NewAmsterdam Pharma in Q2 2023 and has held it in 11 quarters since.
UBS Group's NewAmsterdam Pharma position peaked at $31.6M in Q4 2025.
171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.